Can a 150 mg intramuscular injection of medroxyprogesterone acetate (Depo‑Provera) be used to treat heavy menstrual bleeding in an adult woman?

Depo-Provera 150 mg IM Can Be Used for Heavy Menstrual Bleeding, But It Is Not First-Line Therapy

While Depo-Provera (DMPA) 150 mg IM can effectively reduce heavy menstrual bleeding, it should be considered a second-line option after levonorgestrel-releasing intrauterine systems (LNG-IUS) and tranexamic acid, which demonstrate superior efficacy.

Clinical Context and Evidence Quality

The evidence base for DMPA in treating heavy menstrual bleeding comes primarily from CDC guidelines addressing bleeding irregularities during contraceptive use 1, rather than as primary treatment for pre-existing heavy bleeding. However, recent research directly addresses this clinical question.

Efficacy Data

DMPA Performance in Heavy Menstrual Bleeding

A 2026 prospective cohort study of 240 women demonstrated that injectable DMPA achieved a 78% reduction in PBAC scores at 3 months 2. While effective, this was inferior to LNG-IUS, which showed 93% reduction at 6 months in the same study.

A 2013 pilot study found that DMPA 150 mg IM combined with oral medroxyprogesterone acetate stopped acute abnormal uterine bleeding in all 48 women within 5 days (mean 2.6 days) 3. This suggests DMPA may have particular utility in acute bleeding scenarios.

Comparative Effectiveness

The evidence consistently shows DMPA is less effective than:

• LNG-IUS: A 2010 RCT demonstrated 84.8% treatment success with LNG-IUS versus 22.2% with oral medroxyprogesterone acetate 4
• Tranexamic acid: Multiple studies show superior bleeding reduction with tranexamic acid 2, 5
• Long-cycle oral progestogens (21 days) appear more effective than short-cycle regimens 6

Practical Treatment Algorithm

When to Consider DMPA for Heavy Bleeding:

1. Patient desires contraception simultaneously - DMPA provides dual benefit
2. LNG-IUS contraindicated or refused - anatomical issues, patient preference
3. Acute bleeding management - consider DMPA 150 mg IM plus oral MPA 20 mg q8h × 3 days 3
4. Medical conditions benefiting from DMPA - seizure disorders, sickle cell disease 7

When to Avoid DMPA:

• Adolescents requiring >2 years treatment - bone density concerns 7, 8
• Existing bone disease, eating disorders, or chronic steroid use 7
• Patients unwilling to accept irregular bleeding - common side effect 1, 8
• Desire for rapid return to fertility - 9-18 month delay typical 7, 8

Critical Management Points

Bleeding Pattern Counseling

Before initiating DMPA, explicitly counsel that:

• Irregular bleeding/spotting is nearly universal initially 1
• 55% develop amenorrhea by 1 year, 68% by 2 years 1
• Heavy or prolonged bleeding can paradoxically occur 1

Managing Breakthrough Bleeding on DMPA

If heavy bleeding develops while on DMPA 1, 9:

1. Rule out pathology first: pregnancy, STIs, fibroids, polyps, medication interactions
2. Treatment options during bleeding days:
   • NSAIDs × 5-7 days (first-line)
   • Low-dose COCs or estrogen × 10-20 days (if medically eligible)
3. If bleeding persists and unacceptable: switch to alternative method

Bone Health Monitoring

For DMPA use beyond 2 years 7, 8:

• Ensure 1300 mg calcium + 600 IU vitamin D daily
• Encourage weight-bearing exercise
• Consider bone density testing if additional risk factors
• Strongly consider switching to alternative method

Dosing and Administration

• Standard dose: 150 mg IM every 13 weeks 7, 8
• Grace period: Up to 2 weeks late (15 weeks total) without backup contraception 1
• For acute bleeding: May combine with oral MPA 20 mg q8h × 9 doses 3

Important Caveats

Recent Safety Concerns

A 2026 review identified increased meningioma risk with prolonged medroxyprogesterone acetate exposure 10. While this primarily concerns high-dose oral formulations, it warrants consideration for long-term DMPA users. Systematic assessment for meningioma history is recommended before prescribing.

Other Serious Risks

The FDA label warns of 8:

• Bone density loss (BLACK BOX WARNING)
• Possible slight increase in breast cancer risk
• Venous thromboembolism (though lower risk than estrogen-containing methods)
• Delayed return to fertility

Bottom Line Recommendation

For heavy menstrual bleeding without contraceptive needs, prioritize LNG-IUS or tranexamic acid first 2, 4, 6. DMPA 150 mg IM is reasonable when contraception is desired simultaneously, LNG-IUS is unsuitable, or in acute bleeding scenarios requiring rapid control 3. Limit use to ≤2 years when possible, especially in adolescents 7, 8. Always counsel extensively about bleeding irregularities and bone health before initiation 1.